A Study Based on Japanese Medical Records That Looks at Bleeding Events in People With Atrial Fibrillation and Coronary Artery Disease Who Start Taking Either Dabigatran, Rivaroxaban, or Warfarin

Inclusion Criteria: -≥18 years of age * Has one year of look-back period prior to the index date (defined as the first date of prescription for dabigatran, rivaroxaban, or warfarin during the study period) * New users of warfarin, dabigatran, and rivaroxaban, defined as patients without historic use of any oral anticoagulants during the look-back period * Has at least 1 diagnosis of NVAF during the look-back period prior to or on the index date * Has at least 1 diagnosis of CAD during the look-back period prior to or on the index date Exclusion Criteria: * Diagnosed with end-stage renal disease, or undergo hemodialysis, or experience pregnancy during the study period * Initiate warfarin, dabigatran, rivaroxaban due to valvular Atrial Fibrillation (AF), AF associated with mechanical valve malfunction or mechanical complication of heart valve prosthesis, or rheumatic AF * Underwent joint replacement procedures or diagnosed with venous thromboembolism during the look-back period prior to or on the index date * Prescribed with more than 1 oral anticoagulation (OAC) on the index date * Prescribed with more than 2 anti-platelet drugs per prescription (triple or quadruple anti-platelet use), or prescribed with any anti-platelet injection * Patients with missing or ambiguous age or sex information